Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Indian J Pharmacol. 2011 Nov;43(6):703-6. doi: 10.4103/0253-7613.89830.

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris.

Author information

  • 1Department of Pharmacology, SDM Medical College and Hospital, Sattur, Dharwad, Karnataka, India.

Abstract

OBJECTIVE:

To compare the efficacy and safety profile of dalteparin, a low-molecular-weight heparin with a standard unfractionated heparin in patients with unstable angina pectoris.

MATERIALS AND METHODS:

This was a 6-month, prospective, parallel, randomized and open-labeled study. Patients of angina pectoris were randomized to receive either unfractionated heparin or dalteparin for 5 days. They were followed for 21 days during three visits on 1(st), 5(th) and 21(st) days. A series of resting electrocardiogram were undertaken in all patients on each visit.

RESULTS:

The frequency of the combined clinical outcome of death, myocardial infarction and recurrence of angina was similar during 21 days of follow-up with either dalteparin or intravenous unfractionated heparin. In patients who received dalteparin 2.43% patients developed minor bleeding in the form of epistaxis and 2.5% patients who received unfractionated heparin developed minor bleeding in the form of macroscopic hematuria.

CONCLUSION:

Dalteparin is as effective and safe as unfractionated heparin in the treatment of unstable angina. Dalteparin does not require routine laboratory monitoring as with unfractionated heparin.

KEYWORDS:

Anticoagulant; bleeding; low-molecular-weight heparin; unstable angina

PMID:
22144778
[PubMed]
PMCID:
PMC3229789
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk